Cargando…
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712226/ https://www.ncbi.nlm.nih.gov/pubmed/31441247 http://dx.doi.org/10.4093/dmj.2019.0137 |
_version_ | 1783446638868561920 |
---|---|
author | Kim, Mee Kyoung Ko, Seung-Hyun Kim, Bo-Yeon Kang, Eun Seok Noh, Junghyun Kim, Soo-Kyung Park, Seok-O Hur, Kyu Yeon Chon, Suk Moon, Min Kyong Kim, Nan-Hee Kim, Sang Yong Rhee, Sang Youl Lee, Kang-Woo Kim, Jae Hyeon Rhee, Eun-Jung Chun, SungWan Yu, Sung Hoon Kim, Dae Jung Kwon, Hyuk-Sang Park, Kyong Soo |
author_facet | Kim, Mee Kyoung Ko, Seung-Hyun Kim, Bo-Yeon Kang, Eun Seok Noh, Junghyun Kim, Soo-Kyung Park, Seok-O Hur, Kyu Yeon Chon, Suk Moon, Min Kyong Kim, Nan-Hee Kim, Sang Yong Rhee, Sang Youl Lee, Kang-Woo Kim, Jae Hyeon Rhee, Eun-Jung Chun, SungWan Yu, Sung Hoon Kim, Dae Jung Kwon, Hyuk-Sang Park, Kyong Soo |
author_sort | Kim, Mee Kyoung |
collection | PubMed |
description | The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. |
format | Online Article Text |
id | pubmed-6712226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-67122262019-09-04 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea Kim, Mee Kyoung Ko, Seung-Hyun Kim, Bo-Yeon Kang, Eun Seok Noh, Junghyun Kim, Soo-Kyung Park, Seok-O Hur, Kyu Yeon Chon, Suk Moon, Min Kyong Kim, Nan-Hee Kim, Sang Yong Rhee, Sang Youl Lee, Kang-Woo Kim, Jae Hyeon Rhee, Eun-Jung Chun, SungWan Yu, Sung Hoon Kim, Dae Jung Kwon, Hyuk-Sang Park, Kyong Soo Diabetes Metab J Review The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Korean Diabetes Association 2019-08 2019-08-20 /pmc/articles/PMC6712226/ /pubmed/31441247 http://dx.doi.org/10.4093/dmj.2019.0137 Text en Copyright © 2019 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Kim, Mee Kyoung Ko, Seung-Hyun Kim, Bo-Yeon Kang, Eun Seok Noh, Junghyun Kim, Soo-Kyung Park, Seok-O Hur, Kyu Yeon Chon, Suk Moon, Min Kyong Kim, Nan-Hee Kim, Sang Yong Rhee, Sang Youl Lee, Kang-Woo Kim, Jae Hyeon Rhee, Eun-Jung Chun, SungWan Yu, Sung Hoon Kim, Dae Jung Kwon, Hyuk-Sang Park, Kyong Soo 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea |
title | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea |
title_full | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea |
title_fullStr | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea |
title_full_unstemmed | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea |
title_short | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea |
title_sort | 2019 clinical practice guidelines for type 2 diabetes mellitus in korea |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712226/ https://www.ncbi.nlm.nih.gov/pubmed/31441247 http://dx.doi.org/10.4093/dmj.2019.0137 |
work_keys_str_mv | AT kimmeekyoung 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT koseunghyun 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT kimboyeon 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT kangeunseok 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT nohjunghyun 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT kimsookyung 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT parkseoko 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT hurkyuyeon 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT chonsuk 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT moonminkyong 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT kimnanhee 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT kimsangyong 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT rheesangyoul 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT leekangwoo 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT kimjaehyeon 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT rheeeunjung 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT chunsungwan 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT yusunghoon 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT kimdaejung 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT kwonhyuksang 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT parkkyongsoo 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea AT 2019clinicalpracticeguidelinesfortype2diabetesmellitusinkorea |